This company has been acquired
LogicBio Therapeutics (LOGC) Stock Overview
LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
LOGC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
LogicBio Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.07 |
| 52 Week High | US$3.63 |
| 52 Week Low | US$0.26 |
| Beta | 4.62 |
| 1 Month Change | 0.98% |
| 3 Month Change | 417.63% |
| 1 Year Change | -40.35% |
| 3 Year Change | -76.79% |
| 5 Year Change | n/a |
| Change since IPO | -82.00% |
Recent News & Updates
LogicBio jumps 648% on buyout deal with AstraZeneca unit Alexion
Oct 03Bullish: Analysts Just Made A Notable Upgrade To Their LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Forecasts
Aug 20
LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 18LogicBio GAAP EPS of -$0.15, revenue of $3.2M
Aug 15Recent updates
LogicBio jumps 648% on buyout deal with AstraZeneca unit Alexion
Oct 03Bullish: Analysts Just Made A Notable Upgrade To Their LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Forecasts
Aug 20LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 18LogicBio GAAP EPS of -$0.15, revenue of $3.2M
Aug 15Is LogicBio Therapeutics (NASDAQ:LOGC) Weighed On By Its Debt Load?
Jan 11Does LogicBio Therapeutics (NASDAQ:LOGC) Have A Healthy Balance Sheet?
Aug 18Is LogicBio Therapeutics (NASDAQ:LOGC) Using Debt Sensibly?
Apr 12Is LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Popular Amongst Insiders?
Mar 08The LogicBio Therapeutics (NASDAQ:LOGC) Share Price Has Gained 12% And Shareholders Are Hoping For More
Jan 15Shareholder Returns
| LOGC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.5% | 1.6% | -2.1% |
| 1Y | -40.3% | 16.2% | 9.4% |
Return vs Industry: LOGC underperformed the US Biotechs industry which returned -15.1% over the past year.
Return vs Market: LOGC underperformed the US Market which returned -21.9% over the past year.
Price Volatility
| LOGC volatility | |
|---|---|
| LOGC Average Weekly Movement | 179.9% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LOGC's share price has been volatile over the past 3 months.
Volatility Over Time: LOGC's weekly volatility has increased from 92% to 180% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 62 | Fred Chereau | www.logicbio.com |
LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company’s GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia.
LogicBio Therapeutics, Inc. Fundamentals Summary
| LOGC fundamental statistics | |
|---|---|
| Market cap | US$68.23m |
| Earnings (TTM) | -US$26.54m |
| Revenue (TTM) | US$10.76m |
Is LOGC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LOGC income statement (TTM) | |
|---|---|
| Revenue | US$10.76m |
| Cost of Revenue | US$30.68m |
| Gross Profit | -US$19.92m |
| Other Expenses | US$6.62m |
| Earnings | -US$26.54m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.81 |
| Gross Margin | -185.15% |
| Net Profit Margin | -246.71% |
| Debt/Equity Ratio | 37.7% |
How did LOGC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/11/16 10:04 |
| End of Day Share Price | 2022/11/15 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
LogicBio Therapeutics, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Huidong Wang | Barclays |
| Gbolahan Amusa Benz | Chardan Capital Markets, LLC |
| Silvan Tuerkcan | Citizens JMP Securities, LLC |